Human Platelet Lysate requirements for cell therapy expansion in support of clinical trials

Robert Tressler, San Diego Blood Bank

The  Issue  •  cGMP  manufacture  of  cell  therapies  needs  to  avoid  the  use  

non-­‐human  animal  supplements.  

–  Current  op;ons:  •  Defined  media  

–  Limited  u;lity  to  date  

•  AB  serum  

–  Not  op;mal  for  culture  of  some  cells  

–  Supply  concerns  •  Human  platelet  lysate  (HpL)  

–  Extensive  literature  demonstra;ng  u;lity  of  HpL  for  cell  culture  

–  Mul;ple  companies/organiza;ons  marke;ng  or  developing  HpL  product  formula;ons  »  There  is  variability  in  manufacture  of  HpL    

»  Establishing  a  minimum  set  of  criteria  for  HpL  produc;on/characteriza;on  is  needed  

Why  platelets?  •  The  growth  factors  contained  within  platelets  are  key  factors  for  ;ssue  

repair  and  regenera;on,  vital  to  inducing  cells  to  grow  rapidly,  but  not  abnormally  in  the  body.      

HpL  VS  FBS  Effect  On  CB  MSC  Prolifera;on  

0

5

10

15

20

25

30

35

48hr 72hr 96hr 120hr 144hr

Cel

l Num

ber (

x10e

3)

2% FBS 2% Clearsate

General  Manufacturing  Scheme  for  HpL  Platelets  in  peripheral  blood   Platelets  harvested   Platelets  Washed  

Platelets  flash  frozen  

Platelets  thawed,  membranes  rupture  

Centrifuga;on  Mul;ple  filtra;ons  

Finished  product  

HpL

         HpL  Star;ng  Material  – Typically  expired  platelets  collected  for  transfusion  are  used  as  star;ng  material  •  Collected  at  accredited  (AABB,  FACT)  facili;es  with  that  follow  State  and  CFR  guidelines  for  clinical  blood  products  –  The  appropriate  consent  must  be  obtained  from  donors  prior  to  collec;on  and  use  

–  IDM  and  sterility  tested  prior  to  release  for  manufacture  of  HpL  

–  Assures  a  consistent,  safe,  traceable  star;ng  material  with  QA/QC  oversight  

–  Need  to  finalize  how  “old”  can  expired  platelets  can  be  and  s;ll  be  acceptable  for  use  

         HpL  Produc;on  Process  •  Standardiza;on  of  policies  and  procedures  for  HpL  

manufacturing  processes  assure  produc;on  of  a  safe,  consistent  HpL  product  

•  Manufacturing  processes  should  be  cGMP  compliant,  with  Quality  oversight  –  Environment,  equipment,  personnel,  manufacturing  supplies    

•  Monitoring,  valida;on,  training,  qualifica;on  

•  Implemen;ng  these  prac;ces  for  HpL  produc;on  is  a  key  support  for  cGMP  manufacture  of  the  final  cell  therapy  product  

Lot  to  Lot  Consistency  Assessment  

FBS+bFGF

FBS-bFGF

Lot 1 Clearsate

Lot 2 Clearsate

Lot 3 Clearsate

hMSC proliferation at Day 6 A

mpl

ifica

tion

Yiel

d

2.5% 5% 8%

         Product  Characteriza;on  

•  A  Cer;ficate  of  Analysis  (CoA)  should  be  included  with  each  HpL  manufacturing  lot    

–  Addi;ves*  –  Lot  number  

–  Protein  concentra;on  –  Endotoxin  –  IDM    – Mycoplasma  

–  Sterility  –  Expira;on  Date  *if  used,  for  heparin,  

porcine  source  may    

be  an  issue  

         HpL  Product  Characteriza;on  

•  Stability  – A  stability  plan  may  be  needed  to  determine  shelf  life  of  HpL  products  for  a  specific  storage  condi;on  •  -­‐20  or  -­‐80  C  storage  condi;ons  

– Stability  may  be  assessed  with  an  in  vitro  cell  prolifera;on  potency  assay  •  May  need  to  use  FBS  standard  or  develop  an  HpL  reference  lot  as  comparator  

Potency  Assessment  •  Used  to  support  stability  studies  •  Used  for  HpL  lot  release  criteria  – Poten;al  cell  types  to  be  screened:  • MSCs,  HSCs,  other  

– Cell  counts  taken  at  mul;ple  ;me  points  – Data  compared  to  a  reference  standard  

         HpL  Quality  Control  and  Assurance  

– QA/QC  oversight  is  a  key  aspect  of  HpL  produc;on  to  support  cGMP  cell  therapy  manufacture  

• Release  of  expired  platelets  as  star;ng  material  for  HpL  manufacturing  

• Manufacturing  standardiza;on  to  assure  safety  and  lot-­‐to-­‐lot  consistency  of  the  product  

Sugges;ons  for  FDA  to  Consider    •  A  draa  guidance  for  sourcing  platelets  that  are  the  star;ng  

material  for  HpL  produc;on  –  Transfusion-­‐grade  Platelets  sourced  from  cGMP  facili;es  with  

appropriate  accredita;ons,  Consent  and  Quality  oversight  •  Assures  safety  and  consistency  of  star;ng  material,  typically  expired  platelet  

product  and  s;ll  acceptable  for  HpL  manufacture  

•  A  cGMP  compliant  HpL  manufacturing  process  preferred  with  Quality  program  oversight  suppor;ng  environmental,  equipment,  personnel  and  materials  management  

•  A  CoA  with  each  manufacturing  lot  of  HpL  having  the  minimum  criteria  listed  below:  –  Sterility,  protein  concentra;on,  IDM,  endotoxin,  mycoplasma,  lot  

number,  expira;on  date,  addi;ves  (if  used)  

–  Op;onal:  Growth  factor(s)  content,  potency  assay  results